Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2016

Epigenome-wide association study of triglyceride postprandial
responses to a high-fat dietary challenge
Chao-Qiang Lai
Tufts University

Mary K. Wojczynski
Washington University School of Medicine in St. Louis

Laurence D. Parnell
Tufts University

Bertha A. Hidalgo
University of Alabama, Birmingham

Marguerite Ryan Irvin
University of Alabama, Birmingham

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Lai, Chao-Qiang; Wojczynski, Mary K.; Parnell, Laurence D.; Hidalgo, Bertha A.; Irvin, Marguerite Ryan;
Aslibekyan, Stella; Province, Michael A.; Absher, Devin M.; Arnett, Donna K.; and Ordovas, Jose M.,
,"Epigenome-wide association study of triglyceride postprandial responses to a high-fat dietary challenge."
Journal of Lipid Research. 57,12. 2200-2207. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5586

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Chao-Qiang Lai, Mary K. Wojczynski, Laurence D. Parnell, Bertha A. Hidalgo, Marguerite Ryan Irvin, Stella
Aslibekyan, Michael A. Province, Devin M. Absher, Donna K. Arnett, and Jose M. Ordovas

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/5586

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2016/10/24/jlr.M069948.DC1
.html

 Author’s Choice

patient-oriented and epidemiological research

Epigenome-wide association study of triglyceride
postprandial responses to a high-fat dietary challenge
Chao-Qiang Lai,1,* Mary K. Wojczynski,† Laurence D. Parnell,* Bertha A. Hidalgo,§
Marguerite Ryan Irvin,§ Stella Aslibekyan,§ Michael A. Province,† Devin M. Absher,**
Donna K. Arnett,†† and José M. Ordovás§§

Abstract Postprandial lipemia (PPL), the increased plasma
TG concentration after consuming a high-fat meal, is an independent risk factor for CVD. Individual responses to a meal
high in fat vary greatly, depending on genetic and lifestyle
factors. However, only a few loci have been associated with
TG-PPL response. Heritable epigenomic changes may be significant contributors to the unexplained inter-individual PPL
variability. We conducted an epigenome-wide association
study on 979 subjects with DNA methylation measured from
CD4+ T cells, who were challenged with a high-fat meal as a
part of the Genetics of Lipid Lowering Drugs and Diet Network study. Eight methylation sites encompassing five genes,
LPP, CPT1A, APOA5, SREBF1, and ABCG1, were significantly
associated with PPL response at an epigenome-wide level
(P < 1.1 × 107), but no methylation site reached epigenomewide significance after adjusting for baseline TG levels.
Higher methylation at LPP, APOA5, SREBF1, and ABCG1,
and lower methylation at CPT1A methylation were correlated
with an increased TG-PPL response. These PPL-associated
methylation sites, also correlated with fasting TG, account for
a substantially greater amount of phenotypic variance (14.9%)
in PPL and fasting TG (16.3%) when compared with the genetic contribution of loci identified by our previous genomewide association study (4.5%). In summary, the epigenome
is a large contributor to the variation in PPL, and this has the
potential to be used to modulate PPL and reduce CVD.—
Lai, C-Q., M. K. Wojczynski, L. D. Parnell, B. A. Hidalgo,
M. R. Irvin, S. Aslibekyan, M. A. Province, D. M. Absher,
D. K. Arnett, and J. M. Ordovás. Epigenome-wide association
study of triglyceride postprandial responses to a high-fat dietary challenge. J. Lipid Res. 2016. 57: 2200–2207.
This work was funded by the U.S. Department of Agriculture under agreement
number 8050-51000-098-00D and by National Heart, Lung, and Blood Institute Grant U01-HL072524-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes
of Health. Any opinions, findings, conclusions, or recommendations expressed in
this publication are those of the authors and do not necessarily reflect the view of
the US Department of Agriculture. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information
and does not imply recommendation or endorsement by the US Department of
Agriculture. The USDA is an equal opportunity provider and employer.

Author’s Choice—Final version free via Creative Commons CC-BY license.
Manuscript received 8 June 2016 and in revised form 16 October 2016.
Published, JLR Papers in Press, October 24, 2016
DOI 10.1194/jlr.M069948

Supplementary key words DNA methylation • apolipoproteins • atherosclerosis • diet and dietary lipids • lipoproteins • triglycerides • dietary fat • postprandial lipemia

Postprandial lipemia (PPL) refers to the changes in plasma
lipoproteins following food consumption. PPL is highly
correlated with fasting plasma TG concentrations, yet some
evidence suggests that PPL may be an independent risk factor for CVD (1–4) in ways distinct from fasting TG (5–7).
The risk of CVD that can be independently attributed to
elevated or elongated PPL (factors relating to amount and
time) is supported by the fact that modern humans spend
most of their lifetimes in the postprandial state (2). A persistent and elevated presence of TG-rich lipoprotein (TRL)
particles in the circulation promotes thrombotic processes,
which augment the risk for CVD events (3). PPL varies
greatly among individuals, being defined, in addition to the
characteristics of the food ingested, by age, sex, genetic
variation, and environmental exposures (1, 3). Several
genome-wide association studies (GWASs) for fasting TG
have been performed, revealing over 30 related loci (8, 9).
However, only two GWASs have been conducted for PPL-TG
(10, 11), and only four genetic variants, which are also associated with fasting TG, have been identified in relation to
PPL (9–12). This may result from the limited sample sizes
of these studies combined with the strong environmental
influence on this phenotype (13).
Environmental factors exert significant effects on
gene expression, in some instances through epigenetic
mechanisms (14). Thus, epigenetic marks can be considered

Abbreviations: AUC, area under the whole curve; AUI, area under
the curve increase; EWAS, epigenome-wide association study; GOLDN,
Genetics of Lipid Lowering Drugs and Diet Network; GWAS, genomewide association study; PC, principal component; PPL, postprandial lipemia; TRL, TG-rich lipoprotein.
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MATERIALS AND METHODS
Study population
The GOLDN study, as a part of the National Heart, Lung, and
Blood Institute Family Heart Study, recruited participants (n =
1,327) from families of European descent at two field centers:
Minneapolis, MN and Salt Lake City, UT. GOLDN was designed
as an intervention study to identify genetic factors that determine
lipid responses to two interventions: 1) a high-fat meal test; and 2)
a 3 week treatment of fenofibrate (160 mg). Participants were requested to stop the use of lipid-lowering medication for at least 4
weeks and to refrain from alcohol for 24 h prior to their study
visit. Diet history questionnaires were used to collect demographic,
lifestyle, and dietary data (19). The study protocol was approved
by the Institutional Review Boards at Tufts University, the University of Minnesota, the University of Utah, and the University of
Alabama at Birmingham. All participants provided written consent for the study. The current study comprised a total of 979
participants for whom complete PPL and epigenome data exist.

Postprandial phenotypes
Postprandial TG responses were calculated based on the
growth curve models of TG as the function of times, as described
(10). Briefly, the postprandial phenotypes were estimated as four
measurements: uptake, clearance, area under the whole curve
(AUC), and area under the curve increase (AUI). Uptake was estimated as the slope of the TG response from 0 to 3.5 h after the
meal consumption, a time at which most fat from the meal has
been absorbed (3). Clearance was defined as the downward slope
of the TG level from 3.5 to 6 h after meal consumption, which
measures the speed of the metabolic process that metabolizes the
excess fat from the plasma (3, 20). The AUC was calculated as the
total AUC according to the trapezoid method, and the AUI was
estimated by subtracting the baseline area from the AUC (10).

Epigenome analysis
Different cell types in whole blood may have contrasting methylation patterns. Thus, to minimize the confounding effect of cell
type differences and increase the consistency of methylation measures across samples, we restricted DNA methylome analysis to

CD4+ T cells, which represent the most common lymphocytes in
whole blood (21, 22). Using CD4+ specific antigen magnetic beads
(Invitrogen, Carlsbad, CA), CD4+ T cells were isolated from frozen buffy coat samples that were collected at visit 2 (baseline)
before fenofibrate intervention. DNA was extracted from these
cells using DNeasy kits (Qiagen, Venlo, The Netherlands) (23).
Genome-wide DNA methylation of all DNA samples was quantified
as described (23) using Illumina Infinium human methylation 450K
arrays (Illumina, San Diego, CA), which contain over 485,000
probe sets to measure DNA methylation of over 450,000 CpG sites
across the human genome. Using Illumina’s GenomeStudio package, we estimated the proportion of total signal of methylation for
each probe as the  score, and detection P value as the probability
that the total intensity for a given probe falls within the background
signal intensity. Methylation signals were then further filtered out
if CpG sites met one of the following criteria: 1) detection P > 0.01
and 1.5% of samples have missing data; or 2) >10% of samples
have no adequate intensity (23). For adjustment of the batch effect
across samples, the filtered  scores were normalized separately
for Infinium I and II probe sets using the ComBat package for R
(22, 24, 25). At the end, 464,005 CpG sites passed quality control
and these were used for statistical analysis in this study. To control
for heterogeneity of CD4+ T cells across all samples, principal
components (PCs) based on the  scores of all autosomal CpG
sites that passed quality control were calculated using the prcomp
function in R (v12.12.1). Four PCs were used in the EWAS.

Genome-wide genotyping
The detailed procedure of genome-wide genotyping in GOLDN
has been described (10, 26). In this study, we used the hybrid
genotype data of 2,543,887 SNPs, among which 484,029 were genotyped using the Affymetrix Genome-wide 6.0 Array (Affymetrix,
Santa Clara, CA). The remaining SNPs were imputed using MaCH
software (version 1.0.16) with human genome build 36 as reference, and genotyped SNPs that met the following criteria (27):
call rate >96%, minor allele frequency >1%, and Hardy-Weinberg
equilibrium test P > 106.

Statistical methods
Data analysis design. As the epigenome is known as the fingerprint of individuals in response to lifetime exposures up to the time
point when the samples were collected, an individual epigenotype
depends on local environments. Therefore, individuals with the
same genotype may have different epigenotypes under different
environments. For such reasons, the best discovery and replication
in EWASs should be done within the same population. We randomly split the whole population (n = 979) into two-thirds as a
discovery sample (n = 653) and one-third as a replicate sample (n =
326) using Proc Surveyselect in SAS v9.4 (Cary, NC) while holding
the distributions of baseline TG, BMI, and sex similar between the
two samples. To examine the differences in clinical characteristics
between the sexes among the discovery and replication, we performed a t-test.
Epigenome-wide association. In the discovery stage, we modeled
the association between methylation  score at each CpG site and
PPL response measures using a linear mixed model (28), adjusting
for sex, age, age2, age3, study site, and the first four PCs for T cell
impurity as fixed effects, and kinship as a random effect. The kinship matrix was generated based on family pedigree (29). The
analysis was implemented in SNP and VARIATION SUITE 8.4.3
(GoldenHelix Inc., Bozeman, MT). In addition, we conducted an
EWAS adjusted for an additional covariate of baseline TG. We applied the Bonferroni correction, setting epigenome-wide significance at 1.1 × 107 (25). We subsequently fitted the identical
model in the replication sample (n = 326) for the CpG sites that
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“fingerprints” of that communication between the environment and the genome and some experimental evidence
indicates that diet-induced epigenetic changes can be transmitted through several generations (15, 16). As such, the environment, including habitual diet, may contribute to the
health status of the individual and his/her descendants (17).
We hypothesize that individuals respond to environmental exposures by modulation of the epigenome, which elicits
changes in the PPL response that could alter CVD risk. Of
different forms of epigenetic modification, DNA methylation
is the most extensively studied for its technical feasibility at
the epigenome-wide scale, cost-effectiveness, well-established standard analysis platform, and its apparent relation
to nutrition (18). The objective of this study was to conduct
an epigenome-wide association analysis in order to identify
DNA methylation sites that were associated with PPL-TG
concentrations in response to a high-fat meal in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)
study. In addition, we have characterized DNA sequence
variation in the significant epigenome-wide association
study (EWAS) regions in relation to PPL-TG responses.

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2016/10/24/jlr.M069948.DC1
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were statistically significant in the discovery set for PPL measures.
We corrected the threshold for significance in the replication
stage for multiple testing using the Bonferroni approach, P =
0.05/number of replicated sites. Applying the concept of metaanalysis, we then combined the discovery and replication samples
(i.e., the entire sample n = 979) and repeated the analysis using
the same models (with or without adjusting for the baseline TG)
as in the discovery and replication stages. Because PPL-TG response traits are strongly correlated with fasting TG, we also conducted an EWAS for fasting TG with the entire population using
the same method and model (without adjusting for baseline TG).

Estimation of genetic and epigenetic variance contribution

Relationship between epigenetic markers and genetic
variants
For the CpG sites that showed a significant association, we further examined their correlations with loci previously identified
(10) that were associated with AUC in participants for whom
both epigenome and genome data were available (n = 707). In
addition, we further examined the association of SNPs within a
50 kb region of each CpG site associating with AUC. Data from
previous genetic association studies were retrieved from the
GWAS catalog (30) and gene-environment interactions from
CardioGxE (31).

RESULTS
Demographic and clinical characteristics
The TG-related characteristics of the discovery and replication samples are listed in Table 1. There were no significant differences between the discovery and replication
samples for the TG and PPL response-related phenotypes
(Table 1). However, there were equivalent significant

Epigenome-wide association of PPL
We first conducted epigenome-wide association tests for
each of four PPL-TG traits (Table 2) in the discovery sample
(n = 653). For AUC, we identified four methylation sites in
three genes (CPT1A, APOA5, and SREBF1) that reached
epigenome-wide significance at P  1.1 × 107 (Table 2).
However, when adjusted for baseline TG, no methylation
site reached epigenome-wide significance (supplemental
Table S1). For the other three TG response traits (uptake,
clearance, and AUI), we did not find any methylation sites
that reached epigenome-wide significance either with or
without adjusting for baseline TG. We then replicated the
findings from the discovery stage in the replication sample
(n = 326; Table 2). All four sites that were associated with
AUC in the discovery sample replicated in the second
sample after correction for multiple testing (P < 0.05/4 =
0.0125). After adjustment for baseline TG, only two methylation sites (cg00574958 and cg17058475 at CPT1A) were
replicated in the replication sample (supplemental Table S1).
Applying the concept of meta-analysis, we next conducted a third epigenome-wide association analysis by combining the discovery and replication samples and using the
same models (Table 3). From this analysis, we observed eight
methylation sites that were associated with AUC at the level
of epigenome-wide significance (at P  1.1 × 107; see Table 3, Fig. 1, supplemental Fig. S1). Four of these eight
CpG sites were identified in the initial analysis (Table 2).
The four newly identified sites were in the CPT1A, LPP,
and ABCG1 genes. These four sites were also significantly
associated with AUC in the discovery and replication samples (supplemental Table S2), with P values ranging from
3.39 × 104 to 1.05 × 107. At CPT1A, four CpG sites were
highly correlated with each other, with correlation coefficients ranging from 0.643 to 0.843 (supplemental Table S3)
and similar associations with the AUC. Thus, these four CpG
sites, located at the promotor region of CPT1A, likely represent one methylation region at CPT1A. Interestingly,
three other methylation sites at LPP, SREBF1, and ABCG1
are also correlated with these four CPT1A methylation
sites (supplemental Table S3). In contrast, cg12556569 at
APOA5 was independent of all seven methylation sites,

TABLE 1. Characteristics of discovery and replicate samples in GOLDN
Discovery Sample (n = 653)
Men

n
Age, years
2
BMI, kg/m
Waist, inches
TG at baseline, mg/dl
TG uptake slope
TG clearance slope
TG AUC
TG AUI

313
48.1 (15.9)
28.3 (4.6)
100.0 (13.8)
149.1 (111.0)a
0.18 (0.03)
0.06 (0.05)
31.6 (3.4)b
2.5 (0.5)

Women

Replication Sample (n = 326)
Both

Men

Women

340
653
156
170
326
47.9 (16.4)
48.0 (16.2)
50.2 (17.3)
47.6 (16.4)
48.8 (16.9)
28.2 (6.4)
28.2 (5.6)
28.5 (5.0)
28.2 (6.4)
28.3 (5.8)
93.2 (17.8)
96.5 (16.4) 100.6 (13.6)
93.1 (16.9)
96.7 (15.8)
125.7 (82.2) 136.9 (97.7) 144.4 (90.1) 127.2 (87.3) 135.4 (89.0)
0.17 (0.03)
0.18 (0.03)
0.18 (0.03)
0.18 (0.03)
0.18 (0.03)
0.07 (0.05) 0.07 (0.05) 0.05 (0.05) 0.07 (0.05) 0.06 (0.05)
a
30.4 (3.3)
30.9 (3.4)
31.6 (3.3)
30.3 (3.3)
30.9 (3.4)
2.4 (0.5)
2.4 (0.6)
2.6 (0.6)
2.4 (0.5)
2.5 (0.6)

Values are means (standard deviations).
a
P value for differences between men and women (within sample) significant with P < 0.05.
b
P value for differences between men and women (within sample) significant with P < 0.001.
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Variance contribution of individual methylation sites was estimated using efficient mixed-model association while controlling
for normalized kinship (28) that was calculated based on family
pedigree (29). This procedure was implemented in the Mixed
Linear Model Analysis tools of SNP and VARIATION SUITE 8.4.3
(GoldenHelix Inc., Bozeman, MT). As the identified methylation
sites were not totally independent from each other, the combined
variance contribution of all methylation sites was estimated with
the option of Multi-Locus Mixed Model of the Mixed Linear
Model Analysis while controlling for family relationship and covariates. The variance contribution of the previously identified
genetic variants (rs964184 and rs10243693) that were associated
with AUC (10) was calculated using the same method in participants (n = 707) for whom the genotype data was available.

differences in the baseline TG and TG AUC between sexes
within each sample.

Supplemental Material can be found at:
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TABLE 2. CpG sites associated with AUC in response to a high-fat meal in discovery and replication samples
Discovery (n = 653)
a

Marker

Chr:Position

cg00574958
cg17058475
cg12556569
cg11024682
a

11:68607622
11:68607737
11:116664039
17:17730094

Gene

CPT1A
CPT1A
APOA5
SREBF1

 (SE)

Replication (n = 326)

P

33.24 (4.91)
19.93 (3.57)
3.41 (0.63)
25.41 (4.64)

11

3.02 × 10
3.58 × 108
9.52 × 108
6.10 × 108

 (SE)

P

50.84 (6.27)
33.53 (5.01)
2.61 (0.92)
16.77 (6.03)

1.18 × 1014
1.01 × 1010
4.97 × 103
5.74 × 103

Genomic position was based on genome build 37.

Phenotypic variation of PPL explained by the eight
identified methylation sites
To measure how much variation in AUC can be accounted for by identified epigenetic variants, we estimated
the variance contribution of each significant CpG site to
the phenotypic variance of AUC (Table 3). In particular,
cg00574958 had the largest effect on AUC (9.7%), whereas
cg16464007 at LPP had the smallest contribution of 3.0%.
Four CpG sites at CPT1A contributed a similarly large
amount of variance to PPL phenotype. As all CpG sites,
except cg12556569 at APOA5, are not totally independent
from each other (supplemental Table S3), we estimated the
combined variance contribution of all eight CpG sites together. This yielded a value of 14.9% for AUC variance. As
AUC is strongly correlated with fasting TG, we also estimated the combined variance contribution of the eight
sites to the phenotypic variance of fasting TG and determined this to be 16.3%. In contrast, the genetic variance
contribution of the two previously identified genetic loci
(rs964184 and rs10243693) (10) was estimated as 4.5%
both for AUC and fasting TG, thereby suggesting that the
contribution of epigenetic variants identified in this study
to AUC and fasting TG is substantial in this population.

Correlation between identified methylation sites and
PPL-associated variants
We examined the correlation between the eight identified methylation sites and two genetic variants (rs964184
and rs10243693) that we previously found in GOLDN to
be associated with AUC (10). The methylation level at
cg12556569 at APOA5 was highly correlated (r = 0.689,
P = 2.71 × 10100) with the genotype of SNP rs964184 (supplemental Table S4). However, methylation levels at any of
the identified CpG sites were not associated with the
rs10243693 genotype. In addition, we also examined all
SNPs within 50 kb upstream or downstream of each of the
eight methylation sites for association with AUC. For
cg12556569 at APOA5, there were 20 SNPs (of 71 SNPs in
this region; Fig. 2, supplemental Table S5) that reached
significant association after correction for multiple testing
(P  0.05/71 = 0.0007). For the other seven methylation
sites, none of the SNPs evaluated reached significant association after correction for multiple testing.

DISCUSSION
AUC measures the total change in plasma TG (PPL) and
the duration of these changes after consumption of a highfat meal (10). In terms of the risk for CVD, an increased
AUC indicates elevated levels of atherogenic TRLs and/or
an extended period of time that such lipoproteins remain in
the circulation (2, 3, 5). Our findings highlight the significant contribution of the epigenome to the individual variability in PPL response to a high-fat challenge. PPL is influenced
strongly by environmental factors and these environmental
factors may convey their effects through epigenetic mechanisms. We identified eight methylation CpG sites that were
significantly associated with PPL-TG responses (i.e., AUC) in
our study with 979 subjects of European descent. AUC is
strongly correlated with fasting TG, and we also observed
that these eight methylation sites showed similar strong associations with fasting TG. These methylation sites encompass

TABLE 3. CpG sites associated with AUC in response to a high-fat meal in the full samples (n = 979)
Marker

cg16464007
cg00574958
cg09737197
cg17058475
cg01082498
cg12556569
cg11024682
cg06500161
a

Chr:Positiona

3:188002729
11:68607622
11:68607675
11:68607737
11:68608225
11:116664039
17:17730094
21:43656587

Gene

LPP
CPT1A
CPT1A
CPT1A
CPT1A
APOA5
SREBF1
ABCG1

 (SE)

12.81 (2.32)
38.50 (3.77)
16.79 (2.75)
23.86 (2.84)
43.83 (7.34)
2.94 (0.52)
20.64 (3.63)
16.59 (2.80)

P

AUC Variance Explained
8

4.50 × 10
23
2.69 × 10
1.39 × 109
1.39 × 1016
3.33 × 109
2.30 × 108
1.68 × 108
4.25 × 109

0.030
0.097
0.037
0.068
0.036
0.032
0.032
0.035

Genomic position was based on genome build 37.
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but when adjusting for baseline TG, no methylation site
reached epigenome-wide significance. Lastly, there was no
significant association between methylation sites and the
other three PPL-TG measures of uptake, clearance, and AUI.
In this population, we found that AUC was strongly correlated with fasting TG (Pearson correlation coefficient r =
0.853; supplemental Table S6). We then conducted an EWAS
for fasting TG with the entire population (n = 979) using
the same method, and found six of eight AUC-associated
methylation sites were significantly associated with fasting
TG at the epigenome-wide significance (supplemental
Table S4), and two other sites (cg12556569 and cg11024682)
at APOA5 and SREBF1 almost reached the epigenome-wide
significance (P = 1.47 × 107 and 1.66 × 107, respectively).

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2016/10/24/jlr.M069948.DC1
.html

Fig. 1. Distribution of P values [log10(P value)]
from the epigenome-wide association analysis with
AUC phenotype (n = 979). Eight CpG sites reached
epigenome-wide significance P < 1.1 × 107 (above
the dashed line).

fatty acid -oxidation. Decreased methylation status at the
CPT1A locus has been associated with lipid profile (22, 33),
insulin resistance (25), and metabolic syndrome (34), as
well as obesity (35) in GOLDN, and some of these findings
were replicated in other populations (35). In addition, increased methylation at CPT1A-cg00574958 is correlated with
decreased expression of CPT1A (22, 36) and, more generally,
an inverse relation was seen between CPT1A expression and
changes in TG levels after fish oil supplementation (37).
Interestingly, CpG methylation at CPT1A was noted as 1.49fold higher in adipocytes of obese compared with never
obese women (38). We identified four correlated CpG sites
at CPT1A that strongly associated with AUC (supplemental
Table S3), and decreased methylation of the same four sites
has been associated with increased fasting plasma TG (22).
Moreover, obese subjects show increased PPL responses to
a high-fat meal (9, 39, 40). As the methylation of CPT1A contributes to increased risk of obesity in several populations
(35), it is not surprising that CPT1A methylation is highly
correlated with PPL responses, likely linked to risk of CVD.
The APOA5 genotype is a strong determinant of fasting
TG (41) and PPL-TG (12). We identified SNP rs964184 near
APOA5 as highly associated with PPL-TG (10). In this study,
we found that methylation site cg12556569 (Fig. 2), 903 bp
from the APOA5 transcription start site, was significantly

Fig. 2. Integrated regional overlap of EWAS signals (open squares) and GWAS signals (solid circles) at the APOA5. The x-axis displays the
physical position of CpG sites and SNPs within 50 kb upstream and downstream of the EWAS signal of cg12556569 at APOA5; the y-axis displays log10(P value) of the association.
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five genes: LPP, CPT1A, APOA5, SREBF1, and ABCG1, four
of which encode proteins known to be involved in lipid metabolism. Four CpG sites in CPT1A, APOA5, SREBF1, and
ABCG1 were reported recently to be associated with fasting
TG in two populations of European descent (KORA and
InCHIANTI) (32), lending support to our findings.
Individuals respond diversely to a high-fat meal, with TG
reaching the highest peak 3.5–4 h after the meal and returning to baseline at 10 to 12 h after consumption (5). In the
GOLDN population, AUC was calculated based on measures
at three time points: 0, 3.5, and 6 h after consumption of the
83% fat meal. Previously, our GWAS identified two loci that
were associated with AUC, but such associations were no
longer significant after adjustment for baseline TG (10).
Similarly, in the present study, all eight identified methylation sites did not reach epigenome-wide significance after
adjustment for baseline TG (supplemental Table S1). As
fasting TG was measured from the same blood draw as PPL
in this population, we observed a strong correlation between
fasting TG and AUC (r = 0.853; supplemental Table S6).
Hence, it is not unexpected that identified epigenetic variants that are associated with AUC are also highly correlated
with fasting TG, thus contributing to the risk of CVD.
CPT1A converts cytoplasmic long-chain acyl-CoA to acylcarnitine, which is then transported to mitochondria for
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and baseline TG (see supplemental Table S6). Only AUC is
highly correlated with baseline TG (r = 0.853). The other
three PPL traits are weakly (r = 0.15 for clearance slope),
negatively (r = 0.10 for uptake slope), or not (r = 0.036 for
AUI) correlated with baseline TG. On the other hand, as
the PPL was limited to 6 h with only 3 measures (0, 3.5, and
6 h), AUC may not reflect the length of time needed to
capture the catabolic side of the PPL, and the data points
were not dense enough to precisely calculate the absorption and synthesis of TRLs (and their catabolism). Still,
AUC may provide a more comprehensive view of the overall PPL response than the other three phenotypes. Additionally, the other three PPL traits (intestinal absorption,
chylomicron synthesis, and hepatic TRL catabolism) may
not be properly captured with methylation measures in the
+
CD4 T cells. Therefore, the fact that identified epigenetic
loci are associated with AUC only, not the other three measures of PPL, could reflect the particular characteristics of
epigenetic loci that are induced by the environment.
It is well-established that obese individuals exhibit elevated
postprandial TG in response to a high-fat meal compared
with nonobese individuals (57, 58), but the underlying mechanism is not clear. Because epigenetic markers can affect
both BMI/waist and PPL phenotypes, in our epigenomewide association analysis, BMI or waist were not adjusted in
our linear mixed models. In fact, three of the identified
epigenetic loci, CPT1A-cg00574958, SREBF1-cg11024682,
and ABCG1-cg06500161, were also associated with BMI in
the meta-analysis that was reported recently based on this
population and the Framingham Heart Study (35). To examine the dependence of AUC on obesity, we conducted
EWASs with the entire sample (both discovery and replicate
samples combined) while adjusting for waist or BMI. Indeed, only cg00574958 (and related loci cg17058475 and
cg09737197) at CPT1A remained significant at the epig7
enome-wide level (P < 1.1 × 10 ), while other loci were
6
marginally significant with AUC at P < 5.5 × 10 . In essence, our findings imply that the identified epigenetic loci
at CPT1A, SREBF1, and ABCG1 can link obesity to hyperlipidemia (high TG) and elevated postprandial TG response,
and then to the risk of CVD. This observation potentially
defines a mechanism by which obese subjects show increased PPL response to a high-fat meal, with a subsequent
increased risk for CVD.
Many GWASs have identified genetic loci for a given
trait, but often these loci account for only a small fraction of
genetic variation and phenotypic variation, raising the issue
of missing heritability (59). Within the same population,
we previously conducted a GWAS of PPL-TG response and
identified two variants that were associated with AUC and
reached genome-wide significance (10). However, these
loci explain only about 4.5% of the total phenotypic variation of the PPL response. Diet-induced epigenetic variation
in obesity has been demonstrated recently and is transmissible in mice from one generation to next (15). Here, we
estimated the variance contribution of the identified eight
methylation sites to PPL responses and fasting TG to be
14.9 and 16.3%, respectively. Such a large contribution of the
epigenome to PPL-TG and fasting TG variation is striking.
Epigenetics of the postprandial triglyceride response
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associated with the PPL-TG response. This methylation
site is highly correlated with three SNPs (see supplemental
Table S3): rs964184 (r = 0.689), rs662799 (1131T>C or
600T>C, r = 0.480), and rs3135506 (Ser19Trp, S19W or
56C>G, r = 0.457). The correlation between cg12556569 and
rs964184 was also observed in other populations of European descent (32). Methylation site cg12556569 maps 332
bp upstream of rs662799, a functional variant with a haplotype containing the C allele conferring 46% lower luciferase
activity (transcription) of APOA5 (42). We further showed
that higher methylation levels at cg12556569 are correlated with elevated PPL-TG responses (Table 3). Thus, it is
anticipated that high methylation at this site could be associated with low expression of APOA5, thereby leading to
abnormal metabolism and accumulation of TRLs.
ABCG1, encoding a member of the ABC transporter family, is involved in the efflux of cholesterol and phospholipids
from macrophages into HDL. We observed that higher
methylation levels at cg06500161, near the ABCG1 gene,
were correlated with a high PPL-TG response. Previously,
high DNA methylation levels at ABCG1 have been associated
with increased fasting TG (32, 43). In addition, high methylation levels at this CpG site were shown to be associated with
increased fasting insulin and insulin resistance (25). Furthermore, type 2 diabetes patients showed low expression of
ABCG1 and increased intracellular cholesterol accumulation (44). These observations support the notion that higher
methylation of ABCG1 could lead to an increased CVD risk.
SREBF1, a transcription factor that binds to the sterol regulatory element-1, regulates transcription of the LDL receptor
gene (44). MicroRNA MIR33B, encoded within intron 17 of
SREBF1, targets cholesterol metabolism and fatty acid oxidation genes (45, 46) leading to increases in VLDL-TG (47)
and altered expression of CPT1A (48). Interestingly, a genediet interaction between SREBF1 variant rs2297508 (Gly952Gly) and a high-carbohydrate low-fat diet was reported
for plasma TG in Han Chinese women (49). Still, it remains
unclear whether the epigenetic association observed here exerts impact on SREBF1, MIR33B, or both, but it is intriguing
that this microRNA has been reported to modulate expression of ABCG1 and CPT1A in human liver cells (48, 50).
LPP, also known as LIM domain containing preferred
translocation partner in lipoma, functions in cell-cell adhesion and cell motility, but there is no report in relation to
its potential role in lipid metabolism and PPL responses.
The LPP locus has been identified as associating with type
2 diabetes susceptibility (51, 52) and obesity (53), with CpG
sites found to be age-associated in a set of seven large extended families (54). The CpG site showing association with
TG PPL in this study is about 550 kb from BCL6, a locus identified via TG pathway analysis of GWAS results, as was ABCG1
(55). Moreover, we have noted that the LPP locus appears
to be under positive selection for obesity traits (56), which
may reflect selective pressure from environmental exposure.
All eight identified epigenetic loci in this population are
associated with the AUC-PPL phenotype, but there is no
significant epigenetic locus that is associated with the other
three PPL phenotypes: uptake, clearance, and AUI. We have
examined the correlation between all four PPL phenotypes
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This observation suggests that epigenetic processes may
account for some of the variation that remains unexplained
using the GWAS approach. This underscores the need to
include epigenetic markers with genomic markers and
gene-environment and epistatic interactions in order to
gain a more accurate prediction of CVD risk, and to facilitate
the development of effective strategies for its prevention.
This study has its limitations in the following aspects.
First, one main limitation with the study is the impossibility
to infer the causal relationship between observed DNA
methylation and plasma lipid profile. On the one hand,
DNA methylation of key lipid metabolism genes, such
APOA5, can lead to reduced expression, and then slow
clearance of TG and elevated PPL (12). On the other hand,
it was shown statistically that high TG can also lead to methylation of lipid metabolism genes (CPT1A and SREBF1)
(60). However, the biological and molecular mechanisms
of such a causal relationship remain to be demonstrated.
The second limitation is the constraint of a 6 h timeframe
for the PPL measures with only three time points (0, 3.5,
and 6 h), which may not precisely capture the entire PPL.
An additional limitation of the study is the cell-type specificity and biological relevance of the identified methylation
sites to lipid metabolism. The more relevant tissues for
lipid metabolism are liver and intestine, which are not
available for analysis in a population study. On the other
hand, accumulating evidence suggests methylation sites
that are age-related are commonly shared across many tissues (61). DNA methylation in the blood can serve as a
biomarker of methylation in other tissues (61). As such,
our finding translates from one tissue type to another. Another limitation is that the replication sample of this study
is not fully independent of the discovery sample. Considering strong dependence of epigenetic changes on environment, replication within the same population is justified.
Furthermore, as the AUC of PPL phenotype was measured
in this study in response to consumption of a meal high in
dairy fat (83%), the identified epigenetic loci are likely specific to such dietary challenges and our results might not
be replicated following other diets. Still, the identified loci
map to genes with well-characterized functions in lipid metabolism and homeostasis. On the other hand, based on
the power calculation, the discovery sample has sufficient
power to identify methylation sites that associate with these
PPL phenotypes, as does the replication sample to replicate any findings from the discovery sample.
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